<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pacira Biosciences, Inc. — News on 6ix</title>
<link>https://6ix.com/company/pacira-biosciences-inc</link>
<description>Latest news and press releases for Pacira Biosciences, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pacira-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a9e378dffbe2df10cf4d.webp</url>
<title>Pacira Biosciences, Inc.</title>
<link>https://6ix.com/company/pacira-biosciences-inc</link>
</image>
<item>
<title>Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-files-definitive-proxy-materials-and-mails-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-files-definitive-proxy-materials-and-mails-letter-to-shareholders</guid>
<pubDate>Tue, 28 Apr 2026 20:20:00 GMT</pubDate>
<description>Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA’s Underqualified Nominees BRISBANE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed its definitive proxy materials with the U.S. Securit</description>
</item>
<item>
<title>Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/real-world-data-on-exparelr-shows-reduced-opioid-use-and-lower-total-medical-costs-in-medicare-patients-undergoing-total-hip-arthroplasty</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/real-world-data-on-exparelr-shows-reduced-opioid-use-and-lower-total-medical-costs-in-medicare-patients-undergoing-total-hip-arthroplasty</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, recently announced findings from a real-world study evaluating the clinical and economic impact of EXPAREL® (bupivacaine liposome injectable suspension) on opioi</description>
</item>
<item>
<title>Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative,</description>
</item>
<item>
<title>Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-presents-real-world-data-on-exparelr-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-presents-real-world-data-on-exparelr-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee</description>
</item>
<item>
<title>Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at inv</description>
</item>
<item>
<title>Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-present-real-world-data-on-exparelr-showing-reduced-cost-of-care-at-orthopaedic-research-society-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-present-real-world-data-on-exparelr-showing-reduced-cost-of-care-at-orthopaedic-research-society-2026-annual-meeting</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion --</description>
</item>
<item>
<title>Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reaffirms-commitment-to-shareholder-value-creation</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reaffirms-commitment-to-shareholder-value-creation</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11,</description>
</item>
<item>
<title>Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-participate-in-fireside-chat-at-the-barclays-28th-annual-global-healthcare-conference-9</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-to-participate-in-fireside-chat-at-the-barclays-28th-annual-global-healthcare-conference-9</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative,</description>
</item>
<item>
<title>Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-presents-two-real-world-studies-from-its-innovations-in-genicular-outcomes-registry-igor</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-presents-two-real-world-studies-from-its-innovations-in-genicular-outcomes-registry-igor</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with</description>
</item>
<item>
<title>Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at</description>
</item>
<item>
<title>Pacira to Report 2025 Financial Results on Thursday February 26, 2026</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-report-2025-financial-results-210100686</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-report-2025-financial-results-210100686</guid>
<pubDate>Thu, 12 Feb 2026 21:01:00 GMT</pubDate>
<description>BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners</description>
</item>
<item>
<title>Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-highlights-nopain-act-survey-130000511</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-highlights-nopain-act-survey-130000511</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation’s leading nonpartis</description>
</item>
<item>
<title>Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-appoints-samit-hirawat-md-board-directors-2026-01-28</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-appoints-samit-hirawat-md-board-directors-2026-01-28</guid>
<pubDate>Wed, 28 Jan 2026 05:00:00 GMT</pubDate>
<description>-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira</description>
</item>
<item>
<title>Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-announces-agreement-lg-chem-make-exparelr-available-select-asian-pacific</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-announces-agreement-lg-chem-make-exparelr-available-select-asian-pacific</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–</description>
</item>
<item>
<title>Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenues-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenues-2026</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08,</description>
</item>
<item>
<title>Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-present-44th-annual-jp-morgan-healthcare-conferences-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-present-44th-annual-jp-morgan-healthcare-conferences-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative,</description>
</item>
<item>
<title>DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/doma-perpetual-capital-management-announces-intent-to-nominate-three-highly-qualified-independent-director-candidates-at-2026-annual-meeting-of-pacira-biosciences-inc</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/doma-perpetual-capital-management-announces-intent-to-nominate-three-highly-qualified-independent-director-candidates-at-2026-annual-meeting-of-pacira-biosciences-inc</guid>
<pubDate>Tue, 30 Dec 2025 15:41:00 GMT</pubDate>
<description>DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate three highly-qualified, independent director candidates at the Company's 2026 annual meeting of stockholders. DOMA further asserts the Company's Board of Directors should pursue an immediate sale of the Company. DOMA con</description>
</item>
<item>
<title>Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-joins-probe-consortium-transform-osteoarthritis-research-and-care</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-joins-probe-consortium-transform-osteoarthritis-research-and-care</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals</description>
</item>
<item>
<title>Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid</description>
</item>
<item>
<title>Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain</title>
<link>https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-announces-results-12-month-pilot-study-demonstrating-favorable</link>
<guid isPermaLink="true">https://6ix.com/company/pacira-biosciences-inc/news/pacira-biosciences-announces-results-12-month-pilot-study-demonstrating-favorable</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional</description>
</item>
</channel>
</rss>